ASK4PHARMA CONSULTING
ActiveSummary
ASK4PHARMA CONSULTING has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.5m and a net result of €386,067. Equity has been growing by about 35% per year since 2021. Its solvency ranks better than 92% of 9,652 sector peers (NACE 82, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 04-03-2020 Normal situation
- Activity
- Other business support services NACE 82990
- Establishment unit
- 2.299.921.765 9190 Stekene, since 04-03-2020
- Financial year end
- 31 December
- Peppol
- Reachable since 30-09-2025
Board and ownership
- Smet AnnDirector · since 03-03-2020
- Strobbe KoenraadDirector · since 03-03-2020
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
- Gross margin
- €479,328
- ▲ 7.7%
- Turnover
- ≈ €720,000
- estimated
- Profit
- €386,067
- ▲ 27.5%
- Equity
- €1.5m
- ▲ 31.7%
- Total assets
- €1.6m
- ▲ 30.2%
- 2025 accounts filed 28 days after the deadline
Score breakdownlowers riskSize: total assets €1.6mSector: Office administrative, office support and other business support activities (NACE 82)Figures for financial year 2025 (filed on 28-08-2026)Equity €1.5m (92.7% of total assets)Show the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 82, micro). It does better than 88% of them on solvency, 51% on liquidity, 73% on profitability and 73% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 5 accounts on average 11 days before the deadline. In the sector (NACE 82), the median for financial year 2024 was 7 days before the deadline, and 35% of those companies filed late.
Searched, nothing found (2)
Financials
Financials · financial year 2025, micro format
2025 annual accounts filed 28 days after the deadline Filed on 28 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00439420.
Annual accounts 2025 filed on 28-08-2026 at the NBB all 5 filings
2021 to 2025, 5 financial years
The operating result for 2025 is 8% higher than in 2024. It is the third rise in a row, after the fall in 2022.
Turnover is what the company sold, the result is what was left of it. A loss stands below the zero line.
Assets, equity and debt per financial year.
Above zero, the company can pay its short-term debts with what it holds in the short term.
The EBIT margin is the share of each euro of turnover left from operations. The return on assets is what the assets earn.
The higher the solvency, the better the company absorbs a setback.
A ratio above 1 means the short-term assets cover the short-term debts.
Use the arrow keys on the chart for the figures per year.
The sector band is the middle half of the companies in Office administrative, office support and other business support activities (NACE 82). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30. The dashed line is the median. There is a sector band for net result, equity, total assets, working capital, solvency, current ratio and return on assets (ROA).
Investments
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Tangible fixed assets | €59,614 | €1,330 | - | €7,107 | €19,891 |
| Financial fixed assets | €450 | - | - | - | - |
| Depreciation and write-downs of the year | €11,446 | €10,170 | €10,117 | €10,719 | €10,180 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Comparable companies
These companies have the same main activity as ASK4PHARMA CONSULTING: other business support services (NACE 82990). They are comparable in size and age: total assets between €1.5m and €2.5m, founded between 2017 and 2021.
| Company | Founded | Total assets | Equity | Gross margin | Net result | FTE | Financial year |
|---|---|---|---|---|---|---|---|
| ASK4PHARMA CONSULTING Stekene | 2020 | €1.6m | €1.5m | €0.5m | €0.4m | - | 2025 |
| S.T.E.R. CONSULTING Ham-sur-Heure-Nalinnes | 2019 | €1.5m | €0.3m | €0.4m | €0.3m | - | 2025 |
| GROUP JOLIFE Asse | 2019 | €1.8m | €0.5m | €0.4m | €0.2m | - | 2025 |
| ECOSPHERE HOME Charleroi | 2021 | €1.7m | €0.6m | €0.5m | €0.3m | - | 2025 |
| 2Grow Gent | 2017 | €1.5m | -€1.1m | €0.4m | -€0.3m | 3.4 | 2025 |
| SOLVUS Gent | 2021 | €2.5m | €0.4m | €0.5m | €0.2m | 1 | 2025 |
| LINFIN Management Aubange | 2019 | €1.6m | €0.02m | €0.6m | €0.8m | 0 | 2025 |
They were chosen from the 9,746 other active companies with that main activity and annual accounts from the past two years. All companies with this main activity
Companies with the same profile, two years later
Historical observationIn July 2024, 6,782 companies had the same profile as ASK4PHARMA CONSULTING has now. Two years later, 0.6% had gone bankrupt and 96.7% were still going.
- Small
- 5 to 10 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
That fits the bankruptcy probability of ASK4PHARMA CONSULTING itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,445 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,782 companies, not a prediction for ASK4PHARMA CONSULTING. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €11,446 | €10,170 | €10,117 | €10,719 | €10,180 | ▼ 5.0% |
| Other operating charges640/8 | €2,300 | €1,300 | €1,743 | €1,813 | €2,464 | ▲ 35.9% |
| Gross operating margin9900 | €484,049 | €350,676 | €405,737 | €445,002 | €479,328 | ▲ 7.7% |
| Operating profit (loss)9901 | €470,303 | €339,206 | €393,877 | €432,470 | €466,684 | ▲ 7.9% |
| Financial income75/76B | - | €56 | €20,569 | €19,390 | €55,367 | ▲ 186% |
| Recurring financial income75 | - | €56 | €20,569 | €19,390 | €55,367 | ▲ 186% |
| Financial charges65/66B | €4,803 | €3,040 | €6,378 | €6,839 | €8,566 | ▲ 25.3% |
| Recurring financial charges65 | €4,803 | €3,040 | €6,378 | €6,839 | €8,566 | ▲ 25.3% |
| Profit (loss) for the period before taxes9903 | €465,500 | €336,222 | €408,068 | €445,021 | €513,485 | ▲ 15.4% |
| Income taxes67/77 | €150,841 | €104,380 | €124,310 | €142,119 | €127,418 | ▼ 10.3% |
| Profit (loss) for the period9904 | €314,659 | €231,842 | €283,758 | €302,902 | €386,067 | ▲ 27.5% |
| Transfer to tax-exempt reserves689 | - | - | - | - | €189,450 | - |
| Profit (loss) for the period to be appropriated9905 | €314,659 | €231,842 | €283,758 | €302,902 | €196,617 | ▼ 35.1% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €0.4m | €0.7m | €0.9m | €1.2m | €1.6m | ▲ 30.2% |
| Fixed assets21/28 | €0.05m | €0.04m | €0.03m | €0.03m | €0.04m | ▲ 37.3% |
| Tangible fixed assets22/27 | €0.05m | €0.04m | €0.03m | €0.03m | €0.04m | ▲ 37.9% |
| Land and buildings22 | €0.006m | €0.005m | €0.005m | €0.005m | €0.004m | ▼ 9.1% |
| Furniture and vehicles24 | €0.04m | €0.03m | €0.02m | €0.02m | €0.03m | ▲ 48.1% |
| Financial fixed assets28 | €450 | €450 | €450 | €450 | €450 | = |
| Current assets29/58 | €0.4m | €0.6m | €0.9m | €1.2m | €1.6m | ▲ 30.0% |
| Amounts receivable within one year40/41 | €0.07m | €0.07m | €0.04m | €0.08m | €0.04m | ▼ 50.4% |
| Trade receivables40 | €0.07m | €0.07m | €0.04m | €0.08m | €0.04m | ▼ 53.1% |
| Other amounts receivable41 | €113 | - | €55 | - | €0.002m | - |
| Current investments50/53 | €0.3m | €0.3m | €0.7m | €1.0m | €1.4m | ▲ 37.7% |
| Cash at bank and in hand54/58 | €0.06m | €0.3m | €0.1m | €0.08m | €0.09m | ▲ 10.4% |
| Deferred charges and accrued income490/1 | €0.003m | €0.003m | €0.003m | €0.003m | €0.004m | ▲ 15.2% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €0.4m | €0.7m | €0.9m | €1.2m | €1.6m | ▲ 30.2% |
| Equity10/15 | €0.3m | €0.5m | €0.8m | €1.1m | €1.5m | ▲ 31.7% |
| Contributions10/11 | €0.001m | €0.001m | €0.001m | €0.001m | €0.001m | = |
| Reserves13 | €0.3m | €0.5m | €0.8m | €1.1m | €1.5m | ▲ 31.7% |
| Tax-exempt reserves132 | - | - | - | - | €0.2m | - |
| Distributable reserves133 | €0.3m | €0.5m | €0.8m | €1.1m | €1.3m | ▲ 15.0% |
| Amounts payable17/49 | €0.1m | €0.1m | €0.09m | €0.1m | €0.1m | ▲ 13.0% |
| Amounts payable within one year42/48 | €0.1m | €0.1m | €0.09m | €0.1m | €0.1m | ▲ 13.9% |
| Financial debts43 | €0.001m | €0.002m | €0.001m | €0.002m | €0.006m | ▲ 148% |
| Credit institutions430/8 | €0.001m | €0.002m | €0.001m | €0.002m | €0.006m | ▲ 148% |
| Trade debts44 | €0.003m | €0.004m | €0.01m | €0.003m | €3 | ▼ 99.9% |
| Suppliers440/4 | €0.003m | €0.004m | €0.01m | €0.003m | €3 | ▼ 99.9% |
| Taxes, remuneration and social security45 | €0.06m | €0.06m | €0.03m | €0.04m | €0.03m | ▼ 35.9% |
| Taxes450/3 | €0.06m | €0.06m | €0.03m | €0.04m | €0.03m | ▼ 35.9% |
| Other amounts payable47/48 | €0.05m | €0.05m | €0.05m | €0.05m | €0.08m | ▲ 57.0% |
| Accrued charges and deferred income492/3 | €0.004m | €0.005m | €0.003m | €0.004m | €0.004m | ▼ 8.9% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €314,659 | €231,842 | €283,758 | €302,902 | €386,067 | ▲ 27.5% |
| + Depreciation and write-downs630 | €11,446 | €10,170 | €10,117 | €10,719 | €10,180 | ▼ 5.0% |
| Operating cash flow (approximation) | €326,106 | €242,012 | €293,875 | €313,621 | €396,247 | ▲ 26.3% |
| Investment in fixed assets (approximation) | - | -€1,330 | €0 | -€7,107 | -€19,891 | ▼ 180% |
| Change in cash | - | €252,782 | -€181,694 | -€48,481 | €8,513 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Filings with the National Bank (5)
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 28-08-2026 | 2026-00439420 | NBB |
| 31-12-2024 | micro format | 18-08-2025 | 2025-00380155 | |
| 31-12-2023 | micro format | 24-07-2024 | 2024-00276223 | |
| 31-12-2022 | micro format | 20-06-2023 | 2023-00139104 | |
| 31-12-2021 | micro format | 09-06-2022 | 2022-20056974 |
Board & ownership
Directors
Owners and capital
Owners
Mandate history
- Board
| Name | Functions and periods |
|---|---|
| Smet Ann |
|
| Strobbe Koenraad |
|
Network & group
ASK4PHARMA CONSULTING shares no director with another company.
Connections & network
2 current directorsThe network starts from the directors of ASK4PHARMA CONSULTING. Every other company they run is a node.
Timeline
Acts, filings and financial milestones
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordRegistered office and establishments
Activities
NACEBEL 2025Codes under NACEBEL 2008
Invoicing and payment
Financial year and general meeting
Accounts at the NBBRecognitions · licences · registrations
Legal Entity Identifier
Sites & property
Buildings and parcels at the address
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 46024B0279/00E000 | Flanders | 3,253 m² | 1 · 279 m² | 12.8 m · 3 |